FDA approves Sylvant for multicentric Castleman’s disease

  • April 23, 2014

The FDA today approved siltuximab for treatment of a rare lymphoproliferative disorder that often serves as a precursor to lymphoma.

Siltuximab (Sylvant, Janssen Biotech) is the first FDA-approved drug for multicentric Castleman’s disease (MCD), a form of Castleman’s disease that affects more than a single group of lymph nodes.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
  • Meeting News Coverage
  • OSN meeting
  • ASCRS 2014
  • Live onsite coverage from the Ophthalmology Innovation Summit and the American Society of Cataract and Refractive Surgeons annual meeting in Boston will begin on Thursday, April 24.
  • Health Care Update
  • Medicare lab payments
  • New law will modernize Medicare lab payments: What physicians need to know. Analysis from Arnold & Porter LLP.
More »
More »
More »
More »